drugset / Trial / NCT00376064

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

NCT00376064

Phase 4 Completed 20 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

Timeline

Start
2006-03
Primary completion
2010-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabergoline Small molecule
Subject Octreotide Peptide
Background Pegvisomant Protein / enzyme biologic

Indications